MD4637B1 - Procedeu de obţinere a unui conjugat de hialuronidază cu derivaţi ai polietilenpiperazinei şi aplicarea conjugatului obţinut - Google Patents

Procedeu de obţinere a unui conjugat de hialuronidază cu derivaţi ai polietilenpiperazinei şi aplicarea conjugatului obţinut

Info

Publication number
MD4637B1
MD4637B1 MDA20180043A MD20180043A MD4637B1 MD 4637 B1 MD4637 B1 MD 4637B1 MD A20180043 A MDA20180043 A MD A20180043A MD 20180043 A MD20180043 A MD 20180043A MD 4637 B1 MD4637 B1 MD 4637B1
Authority
MD
Moldova
Prior art keywords
conjugate
ethylene
producing
units
total number
Prior art date
Application number
MDA20180043A
Other languages
English (en)
Russian (ru)
Other versions
MD4637C1 (ro
MD20180043A2 (ro
Inventor
Аркадий Васильевич Некрасов
Темури Мусаевич Карапутадзе
Сергей Алексеевич Медведев
Алесандр Владимирович КОЗЮКОВ
Нино Темуриевна Карапутадзе
Original Assignee
ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НПО Петровакс Фарм"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НПО Петровакс Фарм" filed Critical ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НПО Петровакс Фарм"
Publication of MD20180043A2 publication Critical patent/MD20180043A2/ro
Publication of MD4637B1 publication Critical patent/MD4637B1/ro
Publication of MD4637C1 publication Critical patent/MD4637C1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F26/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F26/06—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a heterocyclic ring containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/02—Alkylation
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/06—Oxidation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Cosmetics (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Invenţia se referă la un procedeu de obţinere a preparatelor enzimatice imobilizate, îndeosebi la obţinerea şi aplicarea unui conjugat de enzimă nou activ cu un purtător polimeric.Conjugatul posedă proprietăţile preparatului Longidază şi inhibă hiperplazia ţesutului conjunctiv, precum şi posedă o acţiune antiinflamatoare şi poate fi utilizat pentru fabricarea unor preparate medicinale cu eliberare prelungită, stabile, active şi inofensive în aplicare, sub formă de supozitor, unguent, injecţie sau cremă cosmetică, precum şi pentru fabricarea preparatelor medicinale de uz veterinar.Procedeul constă în conjugarea hialuronidazei cu un copolimer solubil în apă folosind metoda cu carbodiimidă sau azidă. Pentru conjugare se utilizează un copolimer al N-oxidului 1,4-etilenpiperazinei, (N-carboximetilmetil)-1,4-etilenpiperazinium sau hidrazidei sale, şi al 1,4-etilenpiperazinei cu formula generalăunde n reprezintă 40…90% din numărul total de unităţi;m reprezintă 3…40% din numărul total de unităţi;n+m+l=100 %.
MDA20180043A 2015-12-04 2016-11-09 Procedeu de obţinere a unui conjugat de hialuronidază cu derivaţi ai polietilenpiperazinei şi aplicarea conjugatului obţinut MD4637C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2015152036A RU2616528C1 (ru) 2015-12-04 2015-12-04 Способ получения конъюгата гиалуронидазы с производными полиэтиленпиперазина и применение полученного конъюгата
PCT/RU2016/000755 WO2017095264A1 (ru) 2015-12-04 2016-11-09 Способ получения конъюгата гиалуронидазы с производными полиэтиленпиперазина и применение полученного конъюгата

Publications (3)

Publication Number Publication Date
MD20180043A2 MD20180043A2 (ro) 2018-11-30
MD4637B1 true MD4637B1 (ro) 2019-06-30
MD4637C1 MD4637C1 (ro) 2020-01-31

Family

ID=58642685

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20180043A MD4637C1 (ro) 2015-12-04 2016-11-09 Procedeu de obţinere a unui conjugat de hialuronidază cu derivaţi ai polietilenpiperazinei şi aplicarea conjugatului obţinut

Country Status (19)

Country Link
US (1) US11364283B2 (ro)
EP (1) EP3384917B1 (ro)
JP (1) JP6683827B2 (ro)
KR (2) KR20200131355A (ro)
CN (1) CN108697732B (ro)
AR (1) AR108562A1 (ro)
CA (1) CA3007389C (ro)
EA (1) EA030139B1 (ro)
GE (1) GEP20207131B (ro)
HK (1) HK1259290A1 (ro)
HU (1) HUE056845T2 (ro)
LT (1) LT3384917T (ro)
MD (1) MD4637C1 (ro)
RS (1) RS62659B1 (ro)
RU (1) RU2616528C1 (ro)
SI (1) SI3384917T1 (ro)
TR (1) TR201807851T1 (ro)
UA (1) UA121425C2 (ro)
WO (1) WO2017095264A1 (ro)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11752212B2 (en) 2017-06-29 2023-09-12 University Of Washington N-oxide and ectoine monomers, polymers, their compositions, and related methods
RU2737271C2 (ru) * 2018-06-27 2020-11-26 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НПО Петровакс Фарм" Сополимеры ди-N-оксидов поли-1,4-этиленпиперазина и способы их получения
CN111978404A (zh) * 2020-08-11 2020-11-24 西北大学 基于Halo-tag特异性脱卤反应的蛋白质一步定向固定化方法
KR102481458B1 (ko) 2021-12-15 2022-12-27 홍재혁 문신기구

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2801723B2 (ja) * 1990-01-26 1998-09-21 花王株式会社 新規ベタイン及びそれを含有する分散剤
RU2073031C1 (ru) * 1990-08-06 1997-02-10 Некрасов Аркадий Васильевич Производные поли-1,4-этиленпиперазина, обладающие иммуномодулирующей, противовирусной и антибактериальной активностями
PT789586E (pt) * 1993-09-10 2001-12-28 Petrovax Inc Compostos para a prevencao e tratamento de infeccoes por helmintas
RU2112542C1 (ru) * 1997-02-28 1998-06-10 Аркадий Васильевич Некрасов Препарат для лечения патологических состояний соединительной ткани
RU2185388C2 (ru) * 2000-06-28 2002-07-20 Карапутадзе Темури Мусаевич Способ получения поли-1,4-этиленпиперазина и его производных
EP3192525A1 (en) * 2008-04-14 2017-07-19 Halozyme, Inc. Modified hyaluronidases for use in treating hyaluronan-associated diseases and conditions
RU2417097C2 (ru) * 2008-04-24 2011-04-27 Валерия Леонидовна Багирова Фармацевтическая композиция, содержащая гиалуронидазу и липосомы для наружного применения
RU2428991C9 (ru) * 2010-06-24 2011-12-27 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НПО Петровакс Фарм" Сополимеры гетероцепных алифатических поли-n-оксидов, вакцинирующие и лекарственные средства на их основе
RU2556378C2 (ru) * 2013-07-11 2015-07-10 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НПО Петровакс Фарм" Конъюгат гликопротеина, обладающего активностью эритропоэтина, с производными n-оксида поли-1,4-этиленпиперазина (варианты), фармацевтическая композиция и способ получения конъюгата

Also Published As

Publication number Publication date
JP2019501217A (ja) 2019-01-17
TR201807851T1 (tr) 2018-06-21
MD4637C1 (ro) 2020-01-31
AR108562A1 (es) 2018-09-05
HUE056845T2 (hu) 2022-03-28
LT3384917T (lt) 2021-11-25
CN108697732A (zh) 2018-10-23
KR102358980B1 (ko) 2022-02-08
EP3384917A4 (en) 2019-09-04
EA201650048A1 (ru) 2017-06-30
GEP20207131B (en) 2020-07-10
KR20200131355A (ko) 2020-11-23
KR20180090339A (ko) 2018-08-10
RU2616528C1 (ru) 2017-04-17
MD20180043A2 (ro) 2018-11-30
CA3007389A1 (en) 2017-06-08
SI3384917T1 (sl) 2022-01-31
US20180344815A1 (en) 2018-12-06
HK1259290A1 (zh) 2019-11-29
JP6683827B2 (ja) 2020-04-22
CA3007389C (en) 2021-01-12
CN108697732B (zh) 2021-02-26
US11364283B2 (en) 2022-06-21
RS62659B1 (sr) 2021-12-31
UA121425C2 (uk) 2020-05-25
EP3384917B1 (en) 2021-09-15
EA030139B1 (ru) 2018-06-29
EP3384917A1 (en) 2018-10-10
WO2017095264A1 (ru) 2017-06-08

Similar Documents

Publication Publication Date Title
MD4637C1 (ro) Procedeu de obţinere a unui conjugat de hialuronidază cu derivaţi ai polietilenpiperazinei şi aplicarea conjugatului obţinut
SG11201808167VA (en) Prodrugs of cytotoxic active agents having enzymatically cleavable groups
AU2018338608A1 (en) Methods, compositions, and implantable elements comprising active cells
MX2023009205A (es) Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
EP4324521A3 (en) Treatment of fabry disease in ert-naive and ert-experienced patients
NO20075136L (no) Nye liposompreparater
MX2019010757A (es) Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor.
NO20083287L (no) Medikament for behandling av tumorer, samt anvendelse derav
WO2009105774A3 (en) Amino acid inhibitors of cytochrome p450
EP3501532A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
MX2020013832A (es) Conjugados de ligante/agente activo dirigidos contra cxcr5 que tienen enlazadores escindibles enzimaticamente y un perfil de actividad mejorado.
MX2014004099A (es) Derivados de los factores de coagulacion sanguinea vii y viia, conjugados y complejos que comprenden los mismos, y uso de los mismos.
PE20230091A1 (es) Conjugados terapeuticos
MX2016001607A (es) Microesferas de entecavir y composicion farmaceutica para administracion parenteral que contiene las mismas.
BR112022025918A2 (pt) Compostos de oxazolidinona, composições lipossomais que compreendem compostos de oxazolidinona e métodos de uso dos mesmos
MX2015013155A (es) Formulaciones farmaceuticas de la familia de la tetrandrina y metodo.
MX2023002797A (es) Composiciones activadoras de sting polivalente y usos de las mismas.
UA109544C2 (uk) Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення
IL165807A0 (en) Process for preparing epimerized derivatives of k5polysaccharide with a very high degree of sulfati on and new epi k5-n,o-sulfated polysaccharide derivatives
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2022003051A (es) Formulaciones para la administracion de farmacos.
FR3011850B1 (fr) Vaccin therapeutique contre le cancer a base de proteines de stress rendues immunogenes
PL434014A1 (pl) Nowe pochodne 9H-fluorenu lub ich farmaceutycznie dopuszczalne sole
CR20230472A (es) Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos
MX2023010925A (es) Formulacion inyectable de accion prolongada que comprende risperidona y polimeros biodegradables.

Legal Events

Date Code Title Description
FG4A Patent for invention issued